TN2011000250A1 - Prophylactic/therapeutic agent for cancer - Google Patents

Prophylactic/therapeutic agent for cancer

Info

Publication number
TN2011000250A1
TN2011000250A1 TN2011000250A TN2011000250A TN2011000250A1 TN 2011000250 A1 TN2011000250 A1 TN 2011000250A1 TN 2011000250 A TN2011000250 A TN 2011000250A TN 2011000250 A TN2011000250 A TN 2011000250A TN 2011000250 A1 TN2011000250 A1 TN 2011000250A1
Authority
TN
Tunisia
Prior art keywords
prophylactic
therapeutic agent
cancer
androgen
independent
Prior art date
Application number
TN2011000250A
Other languages
English (en)
Inventor
Hisanori Matsui
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42025816&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000250(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TN2011000250A1 publication Critical patent/TN2011000250A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TN2011000250A 2008-12-29 2011-05-17 Prophylactic/therapeutic agent for cancer TN2011000250A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20388708P 2008-12-29 2008-12-29
PCT/JP2009/071919 WO2010076896A1 (fr) 2008-12-29 2009-12-28 Agent prophylactique/thérapeutique pour le cancer

Publications (1)

Publication Number Publication Date
TN2011000250A1 true TN2011000250A1 (en) 2012-12-17

Family

ID=42025816

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000250A TN2011000250A1 (en) 2008-12-29 2011-05-17 Prophylactic/therapeutic agent for cancer

Country Status (26)

Country Link
US (1) US20110312898A1 (fr)
EP (1) EP2379053A1 (fr)
JP (1) JP2012513982A (fr)
KR (1) KR20110111420A (fr)
CN (1) CN102333520B (fr)
AR (1) AR074918A1 (fr)
AU (1) AU2009334235A1 (fr)
BR (1) BRPI0923663A2 (fr)
CA (1) CA2748517A1 (fr)
CL (1) CL2011001519A1 (fr)
CO (1) CO6382105A2 (fr)
CR (1) CR20110374A (fr)
DO (1) DOP2011000163A (fr)
EA (1) EA019738B1 (fr)
EC (1) ECSP11011166A (fr)
GE (1) GEP20146001B (fr)
IL (1) IL212913A0 (fr)
MA (1) MA32935B1 (fr)
MX (1) MX2011006170A (fr)
NZ (1) NZ593381A (fr)
PE (1) PE20110939A1 (fr)
TN (1) TN2011000250A1 (fr)
TW (1) TW201029660A (fr)
UY (1) UY32367A (fr)
WO (1) WO2010076896A1 (fr)
ZA (1) ZA201103627B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275433B1 (fr) * 2008-04-30 2017-06-07 Kyoto University Dérivé de metastine et son utilisation
CN102665690A (zh) * 2009-12-22 2012-09-12 武田药品工业株式会社 缓释制剂
SG186070A1 (en) * 2010-06-25 2013-01-30 Takeda Pharmaceutical Sustained-release formulation
JP6253146B2 (ja) * 2014-02-04 2017-12-27 国立大学法人山口大学 新規なペプチド誘導体及びこれを含有する医薬
WO2016099232A2 (fr) * 2014-10-20 2016-06-23 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Composé pharmaceutique à effet de traitement et de prévention et procédé de sa préparation
CA3038865A1 (fr) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methodes de traitement de l'infertilite feminine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050090420A (ko) * 2002-12-26 2005-09-13 다케다 야쿠힌 고교 가부시키가이샤 메타스틴 유도체 및 이의 용도
US6800611B2 (en) * 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
ZA200610820B (en) * 2004-06-25 2008-08-27 Takeda Pharmaceutical Metastin derivatives and use thereof
WO2006001499A2 (fr) * 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Derives de metastine et leur utilisation
AR058584A1 (es) * 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos

Also Published As

Publication number Publication date
CL2011001519A1 (es) 2012-03-16
EA019738B1 (ru) 2014-05-30
GEP20146001B (en) 2014-01-10
CA2748517A1 (fr) 2010-07-08
MA32935B1 (fr) 2012-01-02
NZ593381A (en) 2013-01-25
EP2379053A1 (fr) 2011-10-26
TW201029660A (en) 2010-08-16
AR074918A1 (es) 2011-02-23
JP2012513982A (ja) 2012-06-21
CN102333520B (zh) 2013-11-06
EA201100882A1 (ru) 2011-12-30
BRPI0923663A2 (pt) 2016-01-19
AU2009334235A1 (en) 2010-07-08
KR20110111420A (ko) 2011-10-11
WO2010076896A1 (fr) 2010-07-08
PE20110939A1 (es) 2012-01-19
ZA201103627B (en) 2012-09-26
IL212913A0 (en) 2011-07-31
CN102333520A (zh) 2012-01-25
UY32367A (es) 2010-07-30
CO6382105A2 (es) 2012-02-15
CR20110374A (es) 2011-09-19
US20110312898A1 (en) 2011-12-22
MX2011006170A (es) 2011-06-27
DOP2011000163A (es) 2011-07-31
ECSP11011166A (es) 2011-07-29

Similar Documents

Publication Publication Date Title
IN2012DN02046A (fr)
MX2010008817A (es) Tratamiento de cancer de prostata en etapa metastatica con degarelix.
MX2011011431A (es) Composicion para el tratamiento de cancer de prostata.
TN2011000250A1 (en) Prophylactic/therapeutic agent for cancer
EP2303337A4 (fr) Conjugués médicament-ligand à petite molécule pour traitement ciblé contre le cancer
UY31432A1 (es) Compuestos de diarilhidantoina
MX2009003362A (es) Uso de interleucina-10 pegilada para tratamiento de cancer.
MX2009008132A (es) Terapia de combinacion con inhibidores de angiogenesis.
WO2012006584A3 (fr) Régimes thérapeutiques pour les cancers associés à la voie de signalisation hedgehog
MX356801B (es) Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona.
ZA201100904B (en) Therapeutic agent for migraine
EP2295598A4 (fr) Procédé et trousse de détection du cancer, et agent thérapeutique contre le cancer
EP2300040A4 (fr) Procédés et compositions pour immunothérapie du cancer de la prostate
EP2345415A4 (fr) Agent thérapeutique/prophylactique pour le cancer de la prostate
MX2012000203A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer.
EP2450352A4 (fr) Agent prophylactique ou thérapeutique pour le cancer
UA34487U (en) Aquananomagnesium
AU2008100562A4 (en) Genome-based Diagnosis for Prostate Cancer
UA29848U (uk) Застосування системної реконструктивної терапії як способу лікування мігрені
JO3550B1 (ar) مركب لمعالجة سرطان البروستاتا
UA41721U (uk) 1-дезокси-1-n-метиламонію-d-глюцитолу сукцинат
AU2008906236A0 (en) Prostate Cancer Treatment Rectal Probe
JO3525B1 (ar) علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
AU2008900560A0 (en) Prostate cancer biomarkers
UA54810U (ru) Способ спектроэнергетического преобразования частоты излучения